TGFA and breast carcinoma: Subsequently, it was demonstrated that Asp351Gly substitution mutation completely abrogated low estrogenic properties of tamoxifen (full estrogenic properties in case of the endogenous TGFα reporter gene) in a similarly transfected ER-negative MDA-MB-231 breast cancer cells with ER-expressing constructs (74).